Literature DB >> 7781439

Autoimmune cholangitis: a variant of primary biliary cirrhosis. Clinicopathologic and serologic correlations in 200 cases.

Z D Goodman1, P R McNally, D R Davis, K G Ishak.   

Abstract

The term "autoimmune cholangitis" is used for a disease with clinical and pathologic features of primary biliary cirrhosis (PBC) but with negative anti-mitochondrial antibody (AMA) and positive anti-nuclear antibody (ANA) tests. In order to characterize autoimmune cholangitis and to determine whether this truly differs from PBC, we reviewed 200 cases morphologically consistent with PBC in which data on AMA and ANA status were available to us. Of these, 64 (32%) had a negative AMA, 114 (57%) had a positive ANA, and 40 (20%) had negative AMA and positive ANA (autoimmune cholangitis). The AMA-negative group was slightly younger on average (50 vs 55 years) than AMA positives (P < 0.05). There were no significant differences in gender (15.5% male overall), hepatic histopathology, or other laboratory tests between the groups of patients with any of the 4 possible combinations of AMA and ANA. Since the only consistently distinguishing feature among these patients is the autoantibody (AMA and ANA) profile, and they otherwise have virtually identical clinical and histopathologic features, autoimmune cholangitis can be considered to be the same as AMA-negative PBC.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7781439     DOI: 10.1007/bf02065530

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  20 in total

Review 1.  Drug-induced liver disease.

Authors:  J H Lewis; H J Zimmerman
Journal:  Med Clin North Am       Date:  1989-07       Impact factor: 5.456

2.  Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid.

Authors:  Y Calmus; P Gane; P Rouger; R Poupon
Journal:  Hepatology       Date:  1990-01       Impact factor: 17.425

3.  Expression of HLA class I antigens on hepatocytes in liver disease.

Authors:  T Fukusato; M A Gerber; S N Thung; S Ferrone; F Schaffner
Journal:  Am J Pathol       Date:  1986-05       Impact factor: 4.307

Review 4.  Drug-induced chronic liver disease, with emphasis on chronic active hepatitis.

Authors:  L B Seeff
Journal:  Semin Liver Dis       Date:  1981-05       Impact factor: 6.115

5.  [A chronic destructive non-suppurative cholangitis-like disease picture with antinuclear antibodies (immunocholangitis)].

Authors:  G Brunner; O Klinge
Journal:  Dtsch Med Wochenschr       Date:  1987-09-18       Impact factor: 0.628

6.  Necroinflammatory changes in hepatic lobules in primary biliary cirrhosis with less well-defined cholestatic changes.

Authors:  Y Nakanuma
Journal:  Hum Pathol       Date:  1993-04       Impact factor: 3.466

7.  Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis.

Authors:  P Michieletti; I R Wanless; A Katz; P J Scheuer; S J Yeaman; M F Bassendine; J M Palmer; E J Heathcote
Journal:  Gut       Date:  1994-02       Impact factor: 23.059

8.  Immunohistochemical characterization of hepatic lymphocytes in primary biliary cirrhosis in comparison with primary sclerosing cholangitis and autoimmune chronic active hepatitis.

Authors:  E Hashimoto; K D Lindor; H A Homburger; E R Dickson; A J Czaja; R H Wiesner; J Ludwig
Journal:  Mayo Clin Proc       Date:  1993-11       Impact factor: 7.616

9.  Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia.

Authors:  C Degott; G Feldmann; D Larrey; A M Durand-Schneider; D Grange; J P Machayekhi; A Moreau; F Potet; J P Benhamou
Journal:  Hepatology       Date:  1992-02       Impact factor: 17.425

10.  Sequential and diagnostic features in primary biliary cirrhosis based on serial histologic study in 209 patients.

Authors:  B Portmann; H Popper; J Neuberger; R Williams
Journal:  Gastroenterology       Date:  1985-06       Impact factor: 22.682

View more
  19 in total

1.  Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment.

Authors:  M Leuschner; C F Dietrich; T You; C Seidl; J Raedle; G Herrmann; H Ackermann; U Leuschner
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

Review 2.  Primary biliary cirrhosis: new perspectives in diagnosis and treatment.

Authors:  M I Prince; D E Jones
Journal:  Postgrad Med J       Date:  2000-04       Impact factor: 2.401

Review 3.  Autoimmune hepatitis and its variant syndromes.

Authors:  Z Ben-Ari; A J Czaja
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

Review 4.  Variant forms of autoimmune hepatitis.

Authors:  A J Czaja
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

5.  Reversal of cirrhosis in a patient with primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.

Authors:  Thomas M Vallone; Jeremy Ditelberg; Marshall M Kaplan
Journal:  Dig Dis Sci       Date:  2005-01       Impact factor: 3.199

6.  Diagnosing clinical subsets of autoimmune liver diseases based on a multivariable model.

Authors:  Mikio Zeniya; Fumitoki Watanabe; Toshio Morizane; Minoru Shibata; Shiro Maeyama; Masayoshi Kage; Yasuni Nakanuma; Gotaro Toda
Journal:  J Gastroenterol       Date:  2005-12       Impact factor: 7.527

Review 7.  Treatment of autoimmune cholangitis.

Authors:  L Mohr; T Heintges; F Hensel; C Niederau; D Häussinger
Journal:  Dig Dis Sci       Date:  1998-09       Impact factor: 3.199

8.  Autoimmune cholangitis.

Authors:  J Heathcote
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

9.  Pruritus as a presenting symptom of chronic hepatitis C.

Authors:  S C Chia; N V Bergasa; D E Kleiner; Z Goodman; J H Hoofnagle; A M Di Bisceglie
Journal:  Dig Dis Sci       Date:  1998-10       Impact factor: 3.199

10.  'True' antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both?

Authors:  P Muratori; L Muratori; M E Gershwin; A J Czaja; G Pappas; S MacCariello; A Granito; F Cassani; P Loria; M Lenzi; F B Bianchi
Journal:  Clin Exp Immunol       Date:  2004-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.